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Abbreviations Key 
Abbreviation Full Term/Phrase 
ACIP Advisory Committee on Immunization 
Practices 
IPD Invasive Pneumococcal Disease 
MCIR Michigan Care Improvement Registry 
NBS Newborn Screening 
NHLBI National Heart, Lung, and Blood Institute  
PCV-7 7-Valent Pneumococcal Conjugate  
PCV-13 13-Valent Pneumococcal Conjugate Vaccine  
PPSV Pneumococcal Polysaccharide Vaccine  











Children with sickle cell anemia and sickle cell trait are at an increased risk of invasive 
pneumococcal disease compared to children with normal hemoglobin. We assessed and 
compared pneumococcal vaccination status among these three groups.  
 
Procedure  
Children with sickle cell anemia and sickle cell trait were identified using Michigan newborn 
screening records (1997-2014); each child was matched to four children with normal 
hemoglobin based on age, Medicaid enrollment (at least one year from 2012-2014), race, and 
census tract. Vaccination records were obtained from the state’s immunization system. 
Pneumococcal vaccine coverage (PCV7 or PCV13 depending on date of administration) was 
assessed at milestone ages of 3, 5, 7, and 16 months.
 
The proportion of children with vaccine 
coverage at each milestone was calculated overall and compared among children with sickle 
cell anemia, sickle cell trait, and normal hemoglobin using chi-square tests.  
 
Results 
The study population consisted of 355 children with sickle cell anemia, 17,319 with sickle 
cell trait, and 70,757 with normal hemoglobin. The proportion of children with age-
appropriate pneumococcal vaccination coverage was low at each milestone and generally 
decreased over time. Children with sickle cell anemia were more likely to be covered 









Despite higher pneumococcal vaccination coverage among children with sickle cell anemia, 
opportunities for improvement exist among all children. Targeted interventions will benefit 
from mechanisms to identify children with increased risks such as sickle cell anemia or trait 





Invasive pneumococcal disease (IPD), an infection caused by Streptococcus pneumoniae, is a 
significant source of pediatric morbidity and mortality in the United States.
1
 To protect 
against IPD, the Advisory Committee on Immunization Practices (ACIP) established a 
recommendation beginning in 2000 that all children receive four doses of the pneumococcal 
conjugate vaccine (PCV) at 2, 4, 6, and 12 to 15 months of age.
2
  As of 10/6/2000, children 
were recommended to receive the 7-valent PCV formation (PCV7); after 3/12/2010, the 
recommendation was updated to the 13-valent PCV formation (PCV13). Since these 
recommendations, approximately 84% of children have received these four PCV doses by 35 
months of age.
3
 Given the effectiveness of the vaccine, the incidence of IPD has also dropped 
substantially among children less than 5 years old.
1,4,5
 However, an estimated 3,700 deaths in 
the United States still resulted from pneumococcal meningitis and bacteremia in 2013.
6
   
 
Children with chronic conditions are particularly vulnerable to the threat of IPD, such as 
those with cancer, cardiovascular disease, diabetes, or organ transplantations.
7,8
 Sickle cell 
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risk of IPD due to the asplenia experienced by many with the disease.
9
 Without intervention, 
children with sickle cell anemia are over 100 times more likely to have IPD than children 
with normal hemoglobin.
10
 The ACIP recommends that children with specific chronic 
conditions, including sickle cell anemia, should receive the routine four doses of PCV as well 
as one to two additional doses of pneumococcal polysaccharide (PPSV) between the ages of 2 
to 18 years to protect against S. pneumoniae;
1,4,8,11
 this is supported by the National Heart 
Lung and Blood Institute (NHLBI) recommendations.
12
 
Although children with sickle cell anemia are identified as high-risk for IPD, this does not 
extend to sickle cell trait, the carrier status of the disease. Historically, sickle cell trait has 
been considered benign,
13,14
 yet recent reports demonstrate that it may be less asymptomatic 
than previously thought.
13,15,16
 For example, children with sickle cell trait are at an increased 
risk of IPD as compared to children with normal hemoglobin.
17
 Yet, nothing is known 
regarding the pneumococcal vaccination coverage among children with sickle cell trait. This 
may be attributable to difficulty identifying those living with sickle cell trait in the US, as it is 
estimated that only 20% of adults are aware of their carrier status.
18-20
 However, all children 
with sickle cell trait are identified at birth through newborn screening records. Therefore, the 
goal of this study is to use newborn screening records and an immunization registry to assess 
and compare pneumococcal vaccination status among children with sickle cell anemia, sickle 
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METHODS 
This was a cohort study of age-appropriate pneumococcal vaccination coverage among 
children with sickle cell anemia, sickle cell trait, and normal hemoglobin enrolled in 
Michigan Medicaid. This study was deemed exempt by the University of Michigan 




Children enrolled in the Michigan Medicaid program for at least one year during the period 
2012-2014 were eligible for inclusion in our study.  Children with sickle cell anemia and 
sickle cell trait were identified using Michigan newborn screening (NBS) records for all 
births statewide during the period 1997-2014. In this study, children with Hemoglobin (Hb) 
SS and Hb Sβ
0
-rhalassemia were considered to have sickle cell anemia. These children, as 
well as those with sickle cell trait, were linked to Michigan Medicaid records through a 
common electronic birth certificate identifier using a previously validated method.
21
 Since all 
children in Michigan are screened at birth for a wide range of conditions, NBS data served as 
our gold standard for sickle cell anemia and trait case identification. Among children 
identified as sickle cell anemia or trait, those with at least one year of continuous enrollment 
in Michigan Medicaid (2012-2014) were eligible for inclusion in this study. Consistent with 
the Healthcare Effectiveness Data and Information Set (HEDIS) recommendation, children 
enrolled for at least 11 months during any calendar year were considered continuously 
enrolled.
22
 Children with any other forms of health insurance during their Medicaid 
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We created a matched comparison group using Michigan Medicaid records and NBS data. 
For each sickle cell anemia and sickle cell trait case, ten children enrolled in Michigan 
Medicaid - were matched to each case based upon year of birth, year(s) of enrollment in 
Michigan Medicaid, child’s race, and the census tract of residence during Medicaid 
enrollment. These matched children were linked to NBS records using name, date of birth, 
and Medicaid ID.  Only children with confirmed normal hemoglobin were eligible for the 
matched control group; those with abnormal or missing NBS records were excluded. Among 
the remaining eligible children with confirmed normal hemoglobin, four comparison children 
were randomly chosen for each child with sickle cell anemia or trait in the study population. 
Each comparison child with confirmed normal hemoglobin was matched to only one sickle 
cell anemia or trait case across the entire study period. Given the birth cohort of eligible 
children began in 1997, all children were under 18 years of age for all potential years of 
Medicaid enrollment. 
 
As our final step, we linked all children eligible to be in the study population (sickle cell 
anemia, sickle cell trait, and normal hemoglobin) to their corresponding information in the 
state immunization registry, the Michigan Care Improvement Registry (MCIR), based upon 
Medicaid ID, name, and date of birth. Since its inception in 1996, Michigan law has required 
that all vaccination doses administered to persons less than 20 years of age be reported to 
MCIR within 72 hours. The registry is automatically populated by electronic birth records; 
children born in Michigan are loaded into MCIR shortly after birth, regardless of their 
vaccination status. While parents may opt out of the automatic inclusion to MCIR, this is an 
uncommon occurrence and affects fewer than 0.1% of children aged 0-10 years. MCIR 
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Michigan continues to serve as a CDC-funded Sentinel State for the use of registries for 
immunization surveillance.
23,24 Any children that were not matched by exact Medicaid ID 
and/or first and last name, as well as a date of birth within one day were excluded from 
further analysis. Consequently, our final study population consisted of children with sickle 
cell anemia, sickle cell trait, and normal hemoglobin with valid vaccination records in the 
state of Michigan.  
 
Measures 
Using the MCIR IDs obtained from the matching process, pneumococcal vaccination records 
(vaccine type and date administered) were obtained from MCIR for all children in the study 
population. Valid pneumococcal doses obtained met the following conditions: submitted or 
subsequently approved by a provider, not deleted, not duplicated, and a valid dose, per ACIP 
guidance for minimum age and dose intervals.  These doses were used to assess age-
appropriate pneumococcal vaccine coverage for each child at milestone ages of 3, 5, 7, and 
16 months; these milestone ages allow for a one-month grace period following the ACIP 
recommended ages for dose administration. From October 6, 2000 to March 12, 2010, the 
recommended dose of PCV was a seven-strain (PCV7); after that date, children were 
recommended to receive PCV13, the 13-strain formulation. Therefore, doses of PCV7 were 
considered valid between the above dates; doses of PCV13 were considered valid after March 
12, 2010, with a one-year overlap period in which either formulation was considered valid. 
Due to differences in each birth cohort’s age over time and PCV recommendation changes, 
the number of children eligible (i.e. in the denominator) for each age milestone differ, and are 
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Age-appropriate vaccination coverage (yes/no) was based on whether the child had received 
the recommended number of valid pneumococcal vaccines at each age milestone, irrespective 
of disease status (Table 1).
8
  Appropriate coverage was assessed at each child’s milestone 
age, independent of their status at the previous milestone age; however, it was necessary for a 
child to have received all recommended doses by each milestone (Table 1). For example, a 5 
month old child would be considered appropriately covered if they had received two valid 
doses of PCV by that age, irrespective of their coverage at 3 months. In addition, the ACIP 
and NHLBI recommend two doses of PPSV for children with sickle cell anemia.
8,12
 
Therefore, among the children in the study population with sickle cell anemia, age-
appropriate PPSV coverage was conservatively determined at milestones of 5 years plus one 
month, and 10 years plus one month; to be appropriately covered, the child must have also 
received all four PCV doses by these milestone ages (Table 1).  
 
Statistical Analysis 
Frequencies and percentages were calculated for demographic characteristics of children in 
the study population. The proportion of children with age-appropriate vaccine coverage 
(yes/no) at each milestone was calculated overall, and among each group within the study 
population (sickle cell anemia, sickle cell trait, and normal hemoglobin). The proportion of 
children with age-appropriate vaccination coverage was compared across groups using 
Pearson’s chi-square tests; p-values <0.05 were used to determine significant differences. 
When significant differences across groups were present at milestones, two-proportion z-tests 
were performed to identify which study population groups were significantly different in the 
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RESULTS 
From 1997-2014, a total of 592 children with sickle cell anemia and 33,404 children with 
sickle cell trait were born in the state of Michigan. Among these children, 369 (62.3%) with 
sickle cell anemia and 18,274 (54.7%) with sickle cell trait were continuously enrolled in 
Michigan Medicaid (with no gaps in coverage) for at least one year from 2012-2014. A total 
of 196,978 children with potentially normal hemoglobin were identified using Michigan 
Medicaid records linked to their corresponding NBS record; among these children, 6,151 
(3.1%) were excluded due to missing or abnormal hemoglobin status in NBS records. Among 
the 190,827 (96.9%) remaining children, a sample of four children with normal hemoglobin 
(n=74,572) were chosen for each sickle cell anemia and sickle cell trait case, resulting in a 
total of 93,215 children eligible for matching to MCIR records. A total of 88,493 children 
(95%) were successfully matched to their MCIR records.  After excluding the 62 children 
flagged as deceased in Medicaid, the final study groups were 355 with sickle cell anemia, 
17,319 with sickle cell trait, and 70,757 with normal hemoglobin (Fig. 1).   
 
Among all children in the study population, most were black (77.8% of sickle cell anemia, 
81.3% of sickle cell trait, and 81.1% of normal hemoglobin) (Table 2).  There was a slightly 
higher proportion of females to males in the sickle cell anemia group (51.8% female) 
compared to the sickle cell trait (48.9%) and normal hemoglobin (49.3%) groups (Table 2).  
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A total of 279,241 pneumococcal vaccination doses were obtained from MCIR for these 
children, which were administered between January 1, 1997 and May 15, 2017 by a provider, 
and not deleted or duplicated.   
 
Overall, the proportion of children with age-appropriate PCV vaccination coverage generally 
decreased with each successive age milestone, with 69.4% (n=51,680) at 3 months, 49.5% 
(n=37,222) at 5 months, 34.8% (n=26,393) at 7 months, and a small increase to 38.3% 
(n=30,260) at 16 months.  Assessment of age-appropriate PCV vaccination coverage by 
hemoglobin status revealed significant differences in coverage at each age milestone (Fig. 2).  
PCV vaccination coverage was significantly higher among those with sickle cell anemia at 
each milestone, both when compared with sickle cell trait and with normal hemoglobin 
groups individually.  When comparing the sickle cell trait and normal hemoglobin groups, 
vaccination coverage was significantly higher in the normal hemoglobin group at 7 and 16 
months; however, these differences are not clinically meaningful (difference in rates <1%). 
 
Among children with sickle cell anemia, age-appropriate pneumococcal vaccination coverage 
at 5 and 10 years, which included both PCV and PPSV doses, was 64.3% at 5 years and then 
decreased to 52.7% at 10 years.  For comparison, PPSV coverage with this same vaccination 
schedule for children with sickle cell trait and normal hemoglobin (for whom PPSV is not 
routinely recommended) were predictably low, at less than 1% each, and not significantly 










We assessed and compared age-appropriate pneumococcal vaccination coverage among 
children with sickle cell anemia, sickle cell trait, and normal hemoglobin enrolled in 
Michigan Medicaid. Although pneumococcal vaccination coverage was higher among 
children with sickle cell anemia, opportunities for improvement existed among all children. 
Therefore, continued emphasis on programs which increase vaccination coverage is 
necessary to reach 90% coverage as specified by Healthy People 2020.
25
 Emphasis should be 
placed on specific strategies targeting children with sickle cell anemia and sickle cell trait, 





The proportion of children in our study population with age-appropriate coverage at the end 
of the four-dose PCV series was substantially lower than other reports of PCV completion 
rates of 66%-84%.
3,26
 This may be due to the allowance of additional months to complete the 
series in other studies, as well as the characteristics of our study population. Specifically, 
racial disparities exist in PCV vaccination, with black children less likely to receive the four-
dose PCV vaccination series as compared to white children.
27,25
 In addition, children with 
sickle cell anemia tend to live in less affluent census tracts as compared to children without 
sickle cell anemia.
28
 As our study population consisted of children with normal hemoglobin 
that were matched to children with sickle cell anemia and sickle cell trait on race, census 
tract, and Medicaid enrollment, our study population was reflective of a lower socioeconomic 
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whole. Therefore, these rates, although substantially below other reports, are reflective of 
vaccination coverage among a vulnerable group of children.  
 
Compounding the concern of low vaccination coverage in our study population, black 
children and children of lower socioeconomic status are at an increased risk of IPD as 
compared to more white and affluent children.
27,29-31
 Therefore, particular emphasis on 
programs to increase vaccination coverage overall in this population are needed.  The Task 
Force on Community Preventive Services recommends a variety of strategies to improve 
immunization coverage, including reminder/recall, childcare/school vaccination 
requirements, and provider assessment/feedback.
32
  In addition, the Task Force strongly 
recommends multicomponent interventions that include education.
32
 Specific adjustments to 
these methods may result in increased vaccination coverage among vulnerable populations. 
For example, education, assessment, and provision of vaccinations in the context of Women, 
Infants, and Children (WIC) and home visiting programs has been effective at increasing 
receipt of vaccinations among populations of lower socioeconomic status.
32
 In a study of 
parent perceptions regarding reminder/recall approaches, parents with lower education and 
public health insurance for their child were more likely to prefer that reminder/recall 
notifications come from the health department rather than the child’s doctor.
33
 Centralized 
reminder/recall from health departments has also been proven to be more effective at 





Although children with sickle cell anemia had higher vaccination coverage, up to 45% were 
still not adequately vaccinated against IPD by 16 months of age. This is slightly lower than 
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that children with sickle cell anemia were covered at a higher rate than children without 
sickle cell disease, are reflective of other findings.
37,38
 Given the significant room for 
improvement among this particularly vulnerable population, strategies that specifically target 
this subgroup of the population to increase vaccination coverage are necessary. As children 
with sickle cell anemia have at least 8 times the healthcare encounters per year as compared 
to children without sickle cell anemia, strategies that utilize healthcare visits may be most 
effective to increase vaccination coverage.
39-42
 For example, increasing sickle cell-specific 
education of providers about the increased risk of IPD among this population, electronic 
health record prompts to providers, and in-office education of parents, may be effective 
strategies among this high-utilization population. 
 
This study is unique in the ability to assess pneumococcal vaccination coverage in children 
with sickle cell trait. Our results show that these children did not have a meaningfully 
different rate of vaccination coverage as compared to children with normal hemoglobin. This 
is not surprising, as sickle cell trait is not a high-risk condition in which pneumococcal 
vaccination is emphasized; therefore, these children fall under the same recommendations as 
a child with normal hemoglobin. Similarly, children with sickle cell trait are not specifically 
recommended to receive PPSV. However, a comparison of IPD rates among black children 
with sickle cell trait, hemoglobin C trait, or normal hemoglobin enrolled in Medicaid found 
that black children with sickle cell trait have a 77% increased risk of laboratory-confirmed 
IPD as compared to children with normal hemoglobin, even after adjusting for age, gender, 
time (pre-PCV 7, transition year, or post-PCV7), and high risk conditions.
17
 Given the 
potential increased risk of infection among these children, it may be appropriate to emphasize 
pneumococcal vaccination among this population. However, a barrier to outreach to these 
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the child’s sickle cell trait status.
18-20
 This is likely reflective of a lack of follow-up among 
births diagnosed as sickle cell trait, as well as decreased emphasis on primary care physician 
notification and counseling as compared to sickle cell anemia.
19
 A continued neglect of 
opportunities for outreach to those diagnosed with sickle cell trait has been identified as a gap 
in the US healthcare system; development of policies for communication and follow-up of 
sickle cell trait status should be addressed within the US healthcare agenda.
16,19
 In addition, 
further research is necessary to understand the potential increased risk of IPD among children 
with sickle cell trait, as well as their immune response to PPSV vaccination to clarify the role 
that vaccination could play in reducing the susceptibility of this population to IPD. Given that 
8% of all black births in the US are identified as sickle cell carriers,
43
 any increases in 
pneumococcal vaccination coverage or reduction of IPD among this population could 




This study has limitations. First, we were subject to any missing or incorrect data recorded in 
MCIR. In addition, our study population was limited to children enrolled in Michigan 
Medicaid; this may not be generalizable to the population of children as a whole. However, a 
major strength of this paper lies in the identification of children as cases of sickle cell anemia, 
sickle cell trait, or normal hemoglobin using newborn screening records; therefore, the 
misclassification of children by exposure status was nearly non-existent. In addition, we did 
not have data regarding mortality from invasive pneumococcal disease, which would provide 










In conclusion, strategies are necessary to increase pneumococcal vaccination coverage among 
all children. Specific strategies to increase vaccination coverage among the most vulnerable, 
such as children with sickle cell anemia, sickle cell trait, and low socioeconomic status, 
should be emphasized. Without targeting these specific subgroups, racial disparities in both 
pneumococcal vaccination coverage, as well as incidence of IPD, will continue to exist.  
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Milestone Age Assessed Doses Required 
for appropriate 
coverage* 
 Study Populations assessed 
2 months 3 months 1 PCV  All (sickle cell anemia, sickle 
cell trait, normal hemoglobin) 
4 months 5 months 2 PCV  All 
6 months 7 months 3 PCV  All 
12-15 months 16 months 4 PCV  All 
2-5 years 61 months (5 years + 1 
month) 
4 PCV + 1 PPSV  Sickle cell anemia only 
5 years after 
previous dose 
121 months (10 years + 
1 month) 
4 PCV + 2 PPSV  Sickle cell anemia only 
* From October 6, 2000 to March 12, 2010, the recommended dose of PCV was seven-valent 
(PCV7); after that date, children were recommended to receive PCV13, the 13-valent 
formulation. Therefore, doses of PCV7 were considered valid between the above dates; doses 
of PCV13 were considered valid after March 12, 2010, with a one-year overlap period in 
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TABLE 2 Demographic characteristics of study population by hemoglobin status (n = 
88,431) 
    Sickle Cell Anemia     
n = 355 
Sickle Cell Trait          
n = 17,319 
Normal 
Hemoglobin               
n = 70,757 
Race, n (%) White 9 (3%) 1,449 (8%) 5,855 (8%) 
 Black 276 (78%) 14,086 (81%) 57,390 (81%) 
 Native 
American, Other 
0 (0%) 51 (0%) 207 (0%) 
 Unknown 69 (19%) 1,301 (8%) 5,570 (8%) 
 Asian 0 (0%) 4 (0%) 16 (0%) 
Ethnicity, n (%) Hispanic 1 (0%) 428 (2%) 1,719 (2%) 
Sex, n (%) Female 184 (52%) 8,465 (49%) 34,866 (49%) 
 Male 171 (48%) 8,854 (51%) 35,891 (51%) 
Birth Year, n (%) 1997-2002 101 (28%) 4,937 (29%) 20,199 (29%) 
 2003-2008 125 (35%) 6,088 (35%) 24,832 (35%) 
  2009-2014 129 (36%) 6,294 (36%) 25,726 (36%) 
 
 
